<DOC>
	<DOCNO>NCT02645799</DOCNO>
	<brief_summary>The main objective study ass safety , efficacy dose response LABR-312 administer intravenously time percutaneous coronary intervention ( PCI ) drug elute stent reduce restenosis measure Optical Coherence Tomography ( OCT ) 9 month post procedure patient diabetes mellitus ( DM ) . Administration LABR-312 time PCI reduce restenosis compare placebo assess OCT endpoint % neointimal hyperplasia ( % NIH ) volume 9 month patient DM .</brief_summary>
	<brief_title>BLADE-PCI Trial ( BLADE ) ; PHASE IIB LIPOSOMAL ALENDRONATE STUDY</brief_title>
	<detailed_description>This phase IIb , prospective , multi-center , multi-national , randomize , double-blind , two-arm , 1:1 ( escalate dose LABR-312 vs. placebo ) clinical trial . In study arm , target lesion treat Resolute Integrity Drug Eluting Stent index PCI . Lesions plan treat must declare recorded time randomization . Randomization stratify presence absence insulin treatment , HbA1c level ( &lt; 7.5 % vs. ≥7.5 % ) , pre-procedure monocyte count ( ≥500/uL ) . Subjects ( n=~270 ) randomize receive either study drug LABR-312 placebo . Conditionally ongoing safety monitoring , dose escalation LABR-312 study arm perform : 0.01 mg ( first 45 patient vs. 45 patient receive placebo ) , 0.03 mg ( next consecutive 45 patient vs. 45 patient receive placebo ) 0.08 mg ( final 45 consecutive patient vs. 45 patient receive placebo ) . If decision make dose escalate , recruitment continue high dose level deem safe ongoing safety monitoring , approximately 270 subject randomize . In LABR-312 group , 3 dos therefore test , result 6 possibility : Group 1 : Low dose 0.01 mg LABR-312 equivalent volume placebo ( saline ) administer IV . Group 2 : Intermediate dose Up 0.03 mg LABR-312 equivalent volume placebo ( saline ) administer IV . Group 3 : High dose Up 0.08 mg LABR-312 equivalent volume placebo ( saline ) administer IV . The duration subject participation 1 year ; clinical follow-up perform 30 day , 9 month , 1year post randomization . OCT follow-up perform 9 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>General must present 1 . Patient medically treat diabetes mellitus ( insulin oral injectable hypoglycemic medication ) . 2 . Patient eligible indication PCI drug elute stent ( patient may consent prior diagnostic angiography possible PCI ) . 3 . Patient present angina ( stable unstable ) , silent ischemia ( absence symptom must positive stress test , FFR ≤0.80 , angiographic stenosis ≥70 % ) , NSTEMI , recent STEMI ( &gt; 7 day procedure ) . 4 . Nontarget vessel PCI allow prior randomization depend time interval condition follow : During Baseline Procedure : PCI nontarget vessel perform baseline procedure immediately prior randomization , successful uncomplicated , define : &lt; 50 % visually estimate residual diameter stenosis , TIMI Grade 3 flow , dissection ≥ NHLBI type C , perforation , persistent ST segment change , prolong chest pain , TIMI major BARC type 3 bleeding . Less 24 hour prior Baseline Procedure : Not allow ( see exclusion criterion # 2 ) . 24 hours30 day prior Baseline Procedure : PCI nontarget vessel 24 hour 30 day prior randomization successful uncomplicated define . In case nontarget lesion PCI occur 2472 hour prior baseline procedure , least 2 set cardiac biomarkers must draw least 6 12 hour nontarget vessel PCI . If cardiac biomarkers initially elevate local laboratory upper limit normal , serial measurement must demonstrate biomarkers fall . Over 30 day prior Baseline Procedure : PCI nontarget vessel perform great 30 day prior procedure whether successful uncomplicated . 5 . All nontarget lesion ( i.e . meeting angiographic criterion study ) treat prior randomization . All target lesion must plan treated index procedure . The investigator declare target lesion intend treatment time randomization . In event target lesion treat ( e.g . due contrast load ) , stag procedure delay preferably least 2 week index PCI , lesion consider nontarget lesion . Any plan staged lesion must declare end index procedure . 6 . Prior targetvessel PCI allow occur ≥6 month prior randomization restenosis present , reintervention plan restenotic lesion ( ) nontarget lesion . 7 . The patient legal guardian willing able provide write informed consent comply followup visit test schedule . Angiographic Inclusion Criteria ( visual estimate ) ( must present ) : 1 . Target lesion ( ) must locate native coronary artery visually estimate diameter ≥2.25mm ≤4.2mm diameter stenosis ≥50 % &lt; 100 % . 2 . Thrombolysis Myocardial Infarction ( TIMI ) flow 2 3 . If 1 target lesion treat , reference vessel diameter lesion length must meet criterion . General must absent 1 . STEMI within 7 day presentation first treat hospital , whether transfer facility study hospital 2 . PCI within 24 hour prior randomization 3 . Cardiogenic shock ( defined persistent hypotension [ systolic blood pressure &lt; 90 mm Hg ] require pressor hemodynamic support , include IABP ) 4 . Known leave ventricular ejection fraction &lt; 30 % 5 . Relative absolute contraindication DAPT 6 month ( include plan surgery delay chronic oral anticoagulant requirement , atrial fibrillation prosthetic heart valve ) 6 . Hemoglobin &lt; 10 g/dL 7 . Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 8 . White blood cell count &lt; 3,000 cells/mm3 9 . Major clinically significant active infection 10 . Clinically significant liver disease 11 . Renal insufficiency define estimate Glomerular Filtration Rate , GFR &lt; 40 ml/min MDRD formula 12 . Active peptic ulcer active bleeding site 13 . Bleeding site require active medical attention within prior 8 week 14 . History bleed diathesis coagulopathy likely refuse blood transfusion 15 . Cerebrovascular accident ( CVA ) permanent neurological defect result CVA 16 . Known allergy study stent component protocolrequired concomitant medication : alendronate , liposomal medication , aspirin , clopidogrel prasugrel ticagrelor , heparin bivalirudin , iodinate contrast adequately premedicated 17 . Subject take Bisphosphonates , include Alendronate ( Fosamax ) ; Clodronate ( Bonefos ) ; Etidronate ( Didronel / Didrocal ) ; Ibandronate ( Bondronat ) ; Pamidronate ( Aredia ) ; Risedronate ( Actonel ) ; Tiludronate ( Skelid ) ; Zoledronic acid ( Zometa ) , bisphosphonates list . 18 . Any comorbid condition may cause noncompliance protocol ( e.g . dementia , substance abuse , etc . ) reduce life expectancy &lt; 24 month ( e.g . cancer , heart failure , lung disease ) 19 . Patient participate plan participate investigational drug device trial reach primary endpoint . 20 . Women pregnant breastfeeding ( woman childbearing potential must negative pregnancy test within one week index procedure ) . 21 . Women intend become pregnant within 12 month index procedure 22 . Patient receive organ transplant wait list organ transplant . 23 . Patient receive schedule receive chemotherapy within 30 day time index procedure . 24 . Patient receive oral intravenous immunosuppressive therapy know lifelimiting immunosuppressive autoimmune disease . Inhaled steroid steroid use contrastallergy prophylaxis treatment allow . Angiographic Exclusion Criteria ( visual estimate ) ( must absent ) : 1 . Unprotected leave main lesion &gt; 30 % leave main intervention . 2 . Primary PCI STEMIOstial RCA lesion within 5 mm ostium* 3 . Coronary artery disease judge suitable surgical revascularization per guideline local heart team discussion . 4 . Another lesion either target vessel nontarget vessel present require high probability require PCI within 9 month index procedure . 5 . Bifurcation lesion plan high probability dual stent implantation* 6 . Target lesion locate within arterial saphenous vein graft distal diseased arterial saphenous vein graft 7 . Heavily tortuous angulate lesions* 8 . Lesions contain large thrombus* 9 . Total occlusions* 10 . Lesions present within 10mm another lesion treat PCI* 11 . Restenotic lesions* *Refers target lesion . Nontarget lesion meet criterion may treat appropriate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>